Choose language

en
  • bg

  • cs

  • da

  • de

  • el

  • en

  • es

  • et

  • fr

  • hr

  • hu

  • it

  • lt

  • lv

  • nl

  • no

  • pl

  • pt

  • ro

  • ru

  • sk

  • sl

  • sv

  • tr

  • uk

English
  • Български

  • Čeština

  • Danske

  • Deutsch

  • ελληνική

  • English

  • Español

  • Eesti keel

  • Français

  • Hrvatski

  • Magyar

  • Italiano

  • Lietuvių

  • Latviešu

  • Nederlands

  • Norsk

  • Polski

  • Português

  • Română

  • Русский

  • Slovenský

  • Slovenski

  • Svenska

  • Türkçe

  • Українська

How do you prefer to top up your account?

* We don't charge any commission for making deposits into your account

Biogen

BIIB.US $ 338.23 USD

0.04 $ (0.01%)

Growth potential

Recommendation
is being revised

Dividend income

1d
1w
1mo
6mths
All the time

Add to cart

1 lot = 1 stock

Purchase amount:

Brokerage commission:

Transfer commission:

Recommendation

Strong Buy

Performance Rating

DCF

288.69

ROE

0.37

ROA

0.16

P/S

3.3

P/B

4.14

Debt / Equity

0.69

About Company

American Biogen Inc. is a global leader in biotechnology, engaged in scientific research and development of a wide range of medications for treatment of people with hematological, neuralgic and autoimmune diseases. As of today, Biogen is the third largest biotech company in the world. Company's financial gain as of 2015 equaled almost $ 3 billion. Scientific centers and hubs of Biogen Inc. are allocated in over 30 countries, where about 8,000 employees are engaged in various activities. One of the latest projects is Alprolix. It gained a worldwide recognition no more than a year after its first release in 2014 and was highly appraised by Medical Reviewers. Alprolix prevents most fatal bleedings and acts as a prophylactic agent for people with hemophilia.


Sign up for investment ideas from Freedom Finance analysts

We will send an e-mail once a week containing only the most relevant and important information

Congratulations!

Now you will always be aware of which stocks are more profitable to invest in